Shopping Cart 0
Cart Subtotal
AED 0

Heidelberg Pharma AG (WL6) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 2753

Details

Summary

Heidelberg Pharma AG (Heidelberg Pharma) formerly, Wilex AG is a biopharmaceutical company. The company develops therapeutic and diagnostic product candidates for the treatment and specific detection of various cancers. Heidelberg Pharma's pipeline products are focused on treating multiple myeloma, prostate cancer, hematological cancers, metastatic pancreatic cancers, leukemia, non- metastatic ccRCC, kidney cancers and solid tumors. Through its subsidiaries it also provides preclinical contract research services and an antibody drug conjugate (ADC) technology platform. Heidelberg Pharma is headquartered in Ladenburg, Germany.

Heidelberg Pharma AG (WL6)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Heidelberg Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Telix Pharma Enters into Licensing Agreement with Wilex 12

Magenta Therapeutics Enters into Multi-Target Research Agreement with Heidelberg Pharma 13

Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 14

Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 15

Heidelberg Pharma Enters into Agreement with Celonic 16

Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 17

MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 18

Licensing Agreements 19

Magenta Therapeutics Enters into Licensing Agreement with Heidelberg Pharma 19

Heidelberg Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 20

Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 21

RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 22

Wilex Enters Into Licensing Agreement With Link Health For Mesupron 23

Equity Offering 24

Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 24

Wilex Raises USD5.4 Million in Rights Offering of Shares 25

Wilex to Raise USD4.7 Million in Rights Offering of Shares 26

Wilex Raises USD1.81 Million in Private Placement of Shares 27

Wilex Raises USD0.86 Million in Rights Offering of Shares 28

Wilex Raises USD4.4 Million in Right Issue of Shares 29

Wilex Completes Private Placement Of Shares For USD 12.4 Million 30

Wilex Completes Rights Offering Of Shares For USD 7.8 Million 31

Wilex Completes Rights Offering Of Shares For USD 12.6 Million 32

Debt Offering 33

Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 33

Asset Transactions 34

UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 34

Heidelberg Pharma AG-Key Competitors 35

Heidelberg Pharma AG-Key Employees 36

Heidelberg Pharma AG-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Recent Developments 38

Financial Announcements 38

Oct 11, 2018: Heidelberg Pharma AG: Interim management statement on the first nine months of 2018 38

Jul 12, 2018: Heidelberg Pharma reports on first half -year 40

Apr 12, 2018: Heidelberg Pharma: Interim Management Statement on the First Three Months of 2018 42

Mar 22, 2018: Heidelberg Pharma announces financial figures for fiscal year 2017 and provides business update 44

Oct 09, 2017: WILEX: Interim management statement for the first nine months of 2017 47

Jul 13, 2017: WILEX reports on first half-year 50

Apr 12, 2017: WILEX: Interim management statement on the first three months of 2017 52

Mar 30, 2017: WILEX announces financial figures for the 2016 fiscal year and reports on course of business 54

Product News 56

01/24/2017: Antibody against bone marrow tumor developed at MDC is put into application 56

Product Approvals 57

Oct 20, 2017: RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer 57

Clinical Trials 58

Nov 13, 2017: Heidelberg Pharma announces results from research collaboration with Heidelberg University and the DKFZ to be presented at ASH Annual Meeting 58

Oct 19, 2017: RedHill Biopharma Announces Poster Presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 59

Sep 20, 2017: WILEX: Subsidiary Heidelberg Pharma to Present the Proprietary ATAC Technology Platform at the Annual World ADC Summit 60

Sep 18, 2017: RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering use of MESUPRON in Combination Therapy for cancers 61

Other Significant Developments 62

Oct 19, 2018: WILEX successfully completes change of name to Heidelberg Pharma 62

Appendix 63

Methodology 63

About GlobalData 63

Contact Us 63

Disclaimer 63


List Of Figure

List of Figures

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Heidelberg Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Heidelberg Pharma AG, Deals By Therapy Area, 2012 to YTD 2018 9

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Telix Pharma Enters into Licensing Agreement with Wilex 12

Magenta Therapeutics Enters into Multi-Target Research Agreement with Heidelberg Pharma 13

Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 14

Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 15

Heidelberg Pharma Enters into Agreement with Celonic 16

Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 17

MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 18

Magenta Therapeutics Enters into Licensing Agreement with Heidelberg Pharma 19

Heidelberg Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 20

Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 21

RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 22

Wilex Enters Into Licensing Agreement With Link Health For Mesupron 23

Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 24

Wilex Raises USD5.4 Million in Rights Offering of Shares 25

Wilex to Raise USD4.7 Million in Rights Offering of Shares 26

Wilex Raises USD1.81 Million in Private Placement of Shares 27

Wilex Raises USD0.86 Million in Rights Offering of Shares 28

Wilex Raises USD4.4 Million in Right Issue of Shares 29

Wilex Completes Private Placement Of Shares For USD 12.4 Million 30

Wilex Completes Rights Offering Of Shares For USD 7.8 Million 31

Wilex Completes Rights Offering Of Shares For USD 12.6 Million 32

Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 33

UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 34

Heidelberg Pharma AG, Key Competitors 35

Heidelberg Pharma AG, Key Employees 36

Heidelberg Pharma AG, Subsidiaries 37

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Heidelberg Pharma AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Heidelberg Pharma AG (Heidelberg Pharma) formerly, Wilex AG is a biopharmaceutical company. The company develops therapeutic and diagnostic product candidates for the treatment and specific detection of various cancers. Heidelberg Pharma's pipeline products are focused on treating multiple myeloma, prostate cancer, hematological cancers, metastatic pancreatic cancers, leukemia, non- metastatic ccRCC, kidney cancers and solid tumors. Through its subsidiaries it also provides preclinical contract research services and an antibody drug conjugate (ADC) technology platform. Heidelberg Pharma is headquartered in Ladenburg, Germany.

Heidelberg Pharma AG (WL6)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Heidelberg Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Telix Pharma Enters into Licensing Agreement with Wilex 12

Magenta Therapeutics Enters into Multi-Target Research Agreement with Heidelberg Pharma 13

Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 14

Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 15

Heidelberg Pharma Enters into Agreement with Celonic 16

Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 17

MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 18

Licensing Agreements 19

Magenta Therapeutics Enters into Licensing Agreement with Heidelberg Pharma 19

Heidelberg Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 20

Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 21

RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 22

Wilex Enters Into Licensing Agreement With Link Health For Mesupron 23

Equity Offering 24

Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 24

Wilex Raises USD5.4 Million in Rights Offering of Shares 25

Wilex to Raise USD4.7 Million in Rights Offering of Shares 26

Wilex Raises USD1.81 Million in Private Placement of Shares 27

Wilex Raises USD0.86 Million in Rights Offering of Shares 28

Wilex Raises USD4.4 Million in Right Issue of Shares 29

Wilex Completes Private Placement Of Shares For USD 12.4 Million 30

Wilex Completes Rights Offering Of Shares For USD 7.8 Million 31

Wilex Completes Rights Offering Of Shares For USD 12.6 Million 32

Debt Offering 33

Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 33

Asset Transactions 34

UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 34

Heidelberg Pharma AG-Key Competitors 35

Heidelberg Pharma AG-Key Employees 36

Heidelberg Pharma AG-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Recent Developments 38

Financial Announcements 38

Oct 11, 2018: Heidelberg Pharma AG: Interim management statement on the first nine months of 2018 38

Jul 12, 2018: Heidelberg Pharma reports on first half -year 40

Apr 12, 2018: Heidelberg Pharma: Interim Management Statement on the First Three Months of 2018 42

Mar 22, 2018: Heidelberg Pharma announces financial figures for fiscal year 2017 and provides business update 44

Oct 09, 2017: WILEX: Interim management statement for the first nine months of 2017 47

Jul 13, 2017: WILEX reports on first half-year 50

Apr 12, 2017: WILEX: Interim management statement on the first three months of 2017 52

Mar 30, 2017: WILEX announces financial figures for the 2016 fiscal year and reports on course of business 54

Product News 56

01/24/2017: Antibody against bone marrow tumor developed at MDC is put into application 56

Product Approvals 57

Oct 20, 2017: RedHill Biopharma Receives FDA Orphan Drug Designation for MESUPRON for Pancreatic Cancer 57

Clinical Trials 58

Nov 13, 2017: Heidelberg Pharma announces results from research collaboration with Heidelberg University and the DKFZ to be presented at ASH Annual Meeting 58

Oct 19, 2017: RedHill Biopharma Announces Poster Presentation at the 2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 59

Sep 20, 2017: WILEX: Subsidiary Heidelberg Pharma to Present the Proprietary ATAC Technology Platform at the Annual World ADC Summit 60

Sep 18, 2017: RedHill Biopharma Receives Notice of Allowance for a New U.S. Patent Covering use of MESUPRON in Combination Therapy for cancers 61

Other Significant Developments 62

Oct 19, 2018: WILEX successfully completes change of name to Heidelberg Pharma 62

Appendix 63

Methodology 63

About GlobalData 63

Contact Us 63

Disclaimer 63


List Of Figure

List of Figures

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Heidelberg Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Heidelberg Pharma AG, Deals By Therapy Area, 2012 to YTD 2018 9

Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Telix Pharma Enters into Licensing Agreement with Wilex 12

Magenta Therapeutics Enters into Multi-Target Research Agreement with Heidelberg Pharma 13

Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 14

Nordic Nanovector Enters into Research Agreement with Heidelberg Pharma 15

Heidelberg Pharma Enters into Agreement with Celonic 16

Advanced Proteome Therapeutics Enters into Agreement with Heidelberg Pharma 17

MabVax Therapeutics Enters into Co-Development Agreement with Heidelberg Pharma 18

Magenta Therapeutics Enters into Licensing Agreement with Heidelberg Pharma 19

Heidelberg Pharma Enters into Licensing Agreement with University of Texas MD Anderson Cancer Center 20

Heidelberg Pharma Exercises Option for Licensing Agreement with Max Delbruck Center 21

RedHill Biopharma Enters into Licensing Agreement with Wilex for Mesupron 22

Wilex Enters Into Licensing Agreement With Link Health For Mesupron 23

Heidelberg Pharma Raises USD22.8 Million in Rights Offering of Shares 24

Wilex Raises USD5.4 Million in Rights Offering of Shares 25

Wilex to Raise USD4.7 Million in Rights Offering of Shares 26

Wilex Raises USD1.81 Million in Private Placement of Shares 27

Wilex Raises USD0.86 Million in Rights Offering of Shares 28

Wilex Raises USD4.4 Million in Right Issue of Shares 29

Wilex Completes Private Placement Of Shares For USD 12.4 Million 30

Wilex Completes Rights Offering Of Shares For USD 7.8 Million 31

Wilex Completes Rights Offering Of Shares For USD 12.6 Million 32

Heidelberg Pharma Raises USD17.5 Million in Private Placement of Bonds 33

UCB Pharma Re-Acquires Rights For Antibody Program From Wilex For Non-Oncology Indications 34

Heidelberg Pharma AG, Key Competitors 35

Heidelberg Pharma AG, Key Employees 36

Heidelberg Pharma AG, Subsidiaries 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Heidelberg Pharma AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.